A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
暂无分享,去创建一个
D. Dearnaley | R. Huddart | C. Parker | R. Venkitaraman | J. D. de Bono | K. Thomas | V. Murthy | D. Lorente | R. Ahiabor | Lydia U. Parker
[1] D. Zheng,et al. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.
[2] H. Scher,et al. Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). , 2013 .
[3] K. Ovaska,et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. , 2013, Cancer research.
[4] F. Saad,et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[6] J. Bono,et al. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer , 2012, Molecular and Cellular Endocrinology.
[7] I. McEwan,et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. , 2012, Cancer research.
[8] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[9] T. Powles,et al. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol , 2011, British Journal of Cancer.
[10] J. D. de Bono,et al. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Fosså,et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. , 2007, European urology.
[12] Alan Horwich,et al. Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer , 2007, BJU international.
[13] K. Kihara,et al. Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells , 2006, Clinical Cancer Research.
[14] L. Collette,et al. Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.
[15] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[16] E. Small,et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Dakhil,et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. , 2002, The Journal of urology.
[18] Y. Jo,et al. Prostate-Specific Antigen Levels and Prognosis in Patients with Hormone-Refractory Prostate Cancer Treated with Low-Dose Dexamethasone , 2002, Urologia Internationalis.
[19] N Nonomura,et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.
[20] H. Kumon,et al. Treatment of androgen‐independent prostate cancer with dexamethasone: A prospective study in stage D2 patients , 2001, International journal of urology : official journal of the Japanese Urological Association.
[21] T. Miki,et al. Low doses of oral dexamethasone for hormone‐refractory prostate carcinoma , 2000, Cancer.
[22] Donna M. Peehl,et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.
[23] M. Benson,et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. , 2000, The Journal of urology.
[24] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Buckner,et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.
[26] I. Tannock,et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Dorff,et al. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] L. Collette,et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Vassilopoulou-sellin,et al. Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[30] D. Peehl,et al. Erratum: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor (Nature Medicine (2000) 6 (703-706)) , 2000 .